Patient characteristics.

<p>Abbreviations: EGFR-TKI, epidermal growth factor receptor-tyrosine kinase inhibitor; ECOG, Eastern Cooperative Oncology Group; PS, performance status; PD, progressive disease; BSC, best supportive care</p><p>Patient characteristics.</p

Kaplan-Meier Plot.

<p>A, PFS of the patients who received second-line therapy; B, Survival time after termination of EGFR-TKI treatment among patients who received second-line chemotherapy. PFS, progression-free survival.</p

Patient Profile.

<p>EGFR, epidermal growth factor receptor; m+, mutation-positive; PD, progressive disease; BSC, best supportive care.</p

Additional file 1: of A randomized phase II study to assess the effect of adjuvant immunotherapy using α-GalCer-pulsed dendritic cells in the patients with completely resected stage II–IIIA non-small cell lung cancer: study protocol for a randomized controlled trial

SPIRIT 2013 Checklist: recommended items to address in a clinical trial protocol and related documents*. (DOC 123 kb